exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 08, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth...
exagen-logo-440x386-1.jpg
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
September 20, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
Biogen_Logo_Standard-rgb_R.jpg
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
September 07, 2022 17:45 ET | Biogen Inc.
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to...
Allsup Supports “Walk To End Lupus Now 2022” with LFA Heartland Chapter On Saturday, Sept. 10
August 31, 2022 14:12 ET | Allsup
Belleville, Illinois, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Allsup, the nation’s premier disability representation company®, is proud to be sponsoring the “Walk To End Lupus Now 2022-St. Louis”...
Biogen_Logo_Standard-rgb_R.jpg
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
July 28, 2022 07:30 ET | Biogen Inc.
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary...
exagen-logo-440x386-1.jpg
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
July 05, 2022 08:25 ET | Exagen Inc.
SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing...
22157.jpg
Global Systemic Lupus Erythematosus (SLE) Market Report 2022-2026: Featuring Pfizer, AstraZeneca, GlaxoSmithKline and Others
June 29, 2022 06:48 ET | Research and Markets
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with...
exagen-logo-440x386-1.jpg
Exagen Announces Five-Week Campaign for Lupus Awareness Month
May 01, 2022 12:00 ET | Exagen Inc.
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a...
Exagen logo_440x386 (1).jpg
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 08, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December...
Looped In on Lupus Nephritis: American Kidney Fund’s Campaign Focuses on Preventing, Detecting and Managing Lupus Nephritis
February 10, 2022 09:54 ET | American Kidney Fund
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announces its Looped In on Lupus Nephritis campaign, which is aimed at improving diagnosis, awareness and...